Vector Vitale is a pioneering brand that is revolutionizing therapy through the development of innovative therapeutic solutions. They specialize in the correction of biomolecules such as amino acids, polypeptides, and proteins, offering sustainable and effective treatments. With a team of highly skilled experts in physics, chemistry, technology, and life sciences, Vector Vitale combines diverse knowledge to push the boundaries of medicinal advancements.

Founded in 2015 after over two decades of extensive research, Vector Vitale has introduced a groundbreaking therapeutic platform. Their initial focus lies in addressing solid malignant tumors, diabetes, obesity, and Parkinson's disease. However, their ultimate vision extends beyond these diseases.

Vector Vitale aims to redefine the treatment of degenerative disorders by targeting the core factors that contribute to their onset and progression. By creating core pharmaceutical compositions, Vector Vitale aims to provide solutions to the unmet needs of patients suffering from a wide range of degenerative diseases. Their goal is to make these treatments accessible not only to critically ill patients but also to individuals aged 25-60, maximizing their preventative effect and reducing the likelihood of degenerative disorders later in life.

Vector Vitale's technology is built upon the understanding of the human organism as a complex hierarchical multi-level stable system. They recognize that the origin of degenerative diseases lies within amino acids and chemical elements, and therefore, focus on controlling and restoring homeostasis in live cells. Their innovative methods involve correcting defective transcription factors, ribosomes, and protein conformation, as well as controlling the chirality of amino acids in proteins.

Vector Vitale's solutions offer high efficacy without harmful side effects, making them an excellent choice for patients seeking effective and safe treatments. Currently, Vector Vitale is working on creating therapeutic solutions to address primary and metastatic solid tumors. They are in the phase 1 of their study, conducting a First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases.

With their commitment to innovation, Vector Vitale is at the forefront of redefining and advancing therapy for degenerative diseases, providing hope and effective solutions for patients worldwide